Lv31
208 积分 2023-12-20 加入
Primary spinal cord glioblastoma multiforme: a single-center experience
6天前
已完结
A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord
6天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
8天前
已关闭
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
8天前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
12天前
已完结
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
13天前
已完结
1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
13天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
13天前
已完结
EGFR -Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon
13天前
已完结
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
13天前
已完结
皖公网安备34019202002308
